Estadisticas : Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Dalgleish, A.G.
Visitas:2830

2015 ( Estados Unidos de América )

387 ( Reino Unido )

258 ( Singapur )

67 ( Rusia )

23 ( Francia )

20 ( Alemania )

16 ( Letonia )

13 ( China )

8 ( Hong kong )

5 ( Irlanda )

4 ( Finlandia )

3 ( España )

2 ( Canadá )

2 ( Austria )

2 ( Togo )

1 ( Suiza )

1 ( Corea del Sur )

1 ( Australia )

1 ( Brasil )

1 ( Polonia )

Descargas: 829